loading page

Direct detection of ESKAPEc pathogens from whole blood with the use of the T2Bacteria Panel allows early antimicrobial stewardship intervention in patients with sepsis
  • +11
  • Pavel Drevinek,
  • Jakub Hurych,
  • Milena Antuskova,
  • Jan Tkadlec,
  • Jan Berousek,
  • Zuzana Prikrylova,
  • Jiri Bures,
  • Jaromir Vajter,
  • Martin Soucek,
  • Jan Masopust,
  • Vendula Martinkova,
  • Jaroslava Adamkova,
  • Veronika Hysperska,
  • Eliska Bebrova
Pavel Drevinek
Motol University Hospital
Author Profile
Jakub Hurych
Motol University Hospital
Author Profile
Milena Antuskova
Motol University Hospital
Author Profile
Jan Tkadlec
Motol University Hospital
Author Profile
Jan Berousek
Charles University
Author Profile
Zuzana Prikrylova
Motol University Hospital
Author Profile
Jiri Bures
Motol University Hospital
Author Profile
Jaromir Vajter
Motol University Hospital
Author Profile
Martin Soucek
Motol University Hospital
Author Profile
Jan Masopust
Motol University Hospital
Author Profile
Vendula Martinkova
Motol University Hospital
Author Profile
Jaroslava Adamkova
Motol University Hospital
Author Profile
Veronika Hysperska
Motol University Hospital
Author Profile
Eliska Bebrova
Motol University Hospital
Author Profile

Abstract

In the microbiological diagnosis of bloodstream infections (BSI), blood culture (BC) is considered the gold standard test despite its limitations such as low sensitivity and slow turnaround time. A new FDA-cleared and CE-marked platform utilizing magnetic resonance to detect amplified DNA of the six most common and/or problematic BSI pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli) is available and may shorten the time to diagnosis and potentially improve antimicrobial utilization. Whole blood samples from hospitalized patients with clinical signs of sepsis were analyzed using the T2Bacteria Panel (T2Biosystems) and compared to simultaneously collected BC. Discrepant results were evaluated based on clinical infection criteria, combining supporting culture results and the opinion of treating physicians. A total of 55 samples from 53 patients were evaluated. The sensitivity and specificity of the T2Bacteria panel was 94% (16 out of 17 detections of T2Bacteria-targeted organisms) and 100%, respectively, with 36.4% (8 of 22) causes of BSI detected only by this method. The T2Bacteria Panel detected pathogens on average 55 hours faster than standard BC. In our study, 9 of 15 patients with positive T2Bacteria Panel results received early-targeted antibiotic therapy, and/or their antimicrobial treatment was modified based on T2Bacteria Panel findings. Given the high reliability, faster time to detection, and easy workflow, the technique qualifies as a point of care testing approach.

Peer review status:ACCEPTED

24 Jan 2021Submitted to MicrobiologyOpen
25 Jan 2021Submission Checks Completed
25 Jan 2021Assigned to Editor
26 Jan 2021Reviewer(s) Assigned
13 Feb 2021Review(s) Completed, Editorial Evaluation Pending
15 Feb 2021Editorial Decision: Revise Minor
08 Apr 20211st Revision Received
09 Apr 2021Assigned to Editor
09 Apr 2021Submission Checks Completed
09 Apr 2021Review(s) Completed, Editorial Evaluation Pending
09 Apr 2021Reviewer(s) Assigned
06 May 2021Editorial Decision: Revise Minor
10 May 20212nd Revision Received
11 May 2021Assigned to Editor
11 May 2021Submission Checks Completed
11 May 2021Review(s) Completed, Editorial Evaluation Pending
17 May 2021Editorial Decision: Accept